vs
OFG BANCORP（OFG）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是OFG BANCORP的1.1倍（$207.3M vs $184.3M），OFG BANCORP净利率更高（30.3% vs -62.0%，领先92.3%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 0.9%），OFG BANCORP自由现金流更多（$199.3M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 2.8%）
OFG Bancorp成立于1964年，总部位于波多黎各圣胡安，是东方银行的金融控股公司。公司通过东方银行、东方金融服务有限责任公司、东方保险有限责任公司等核心子公司，主要面向波多黎各和美属维尔京群岛市场，提供多元化的零售与商业银行、贷款、财富管理相关产品、服务及技术解决方案。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
OFG vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $184.3M | $207.3M |
| 净利润 | $55.9M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 25.7% | -54.7% |
| 净利率 | 30.3% | -62.0% |
| 营收同比 | 0.9% | 25.9% |
| 净利润同比 | 11.0% | 3.5% |
| 每股收益（稀释后） | $1.27 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $184.3M | $207.3M | ||
| Q3 25 | $186.2M | $159.9M | ||
| Q2 25 | $182.4M | $166.5M | ||
| Q1 25 | $178.6M | $139.3M | ||
| Q4 24 | $182.7M | $164.6M | ||
| Q3 24 | $174.7M | $139.5M | ||
| Q2 24 | $179.8M | $147.0M | ||
| Q1 24 | $174.4M | $108.8M |
| Q4 25 | $55.9M | $-128.6M | ||
| Q3 25 | $51.8M | $-180.4M | ||
| Q2 25 | $51.8M | $-115.0M | ||
| Q1 25 | $45.6M | $-151.1M | ||
| Q4 24 | $50.3M | $-133.2M | ||
| Q3 24 | $47.0M | $-133.5M | ||
| Q2 24 | $51.1M | $-131.6M | ||
| Q1 24 | $49.7M | $-170.7M |
| Q4 25 | 25.7% | -54.7% | ||
| Q3 25 | 33.0% | -106.9% | ||
| Q2 25 | 36.1% | -64.8% | ||
| Q1 25 | 33.3% | -102.6% | ||
| Q4 24 | 28.9% | -74.3% | ||
| Q3 24 | 35.4% | -94.6% | ||
| Q2 24 | 39.6% | -79.1% | ||
| Q1 24 | 38.9% | -151.9% |
| Q4 25 | 30.3% | -62.0% | ||
| Q3 25 | 27.8% | -112.8% | ||
| Q2 25 | 28.4% | -69.0% | ||
| Q1 25 | 25.5% | -108.5% | ||
| Q4 24 | 27.6% | -80.9% | ||
| Q3 24 | 26.9% | -95.7% | ||
| Q2 24 | 28.4% | -89.5% | ||
| Q1 24 | 28.5% | -156.8% |
| Q4 25 | $1.27 | $-1.28 | ||
| Q3 25 | $1.16 | $-1.81 | ||
| Q2 25 | $1.15 | $-1.17 | ||
| Q1 25 | $1.00 | $-1.57 | ||
| Q4 24 | $1.10 | $-1.34 | ||
| Q3 24 | $1.00 | $-1.40 | ||
| Q2 24 | $1.08 | $-1.52 | ||
| Q1 24 | $1.05 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.0B | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.4B | $-80.0M |
| 总资产 | $12.5B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $1.0B | $421.0M | ||
| Q3 25 | $740.3M | $202.5M | ||
| Q2 25 | $851.8M | $176.3M | ||
| Q1 25 | $710.6M | $127.1M | ||
| Q4 24 | $591.1M | $174.0M | ||
| Q3 24 | $680.6M | $150.6M | ||
| Q2 24 | $740.4M | $480.7M | ||
| Q1 24 | $754.4M | $112.3M |
| Q4 25 | $1.4B | $-80.0M | ||
| Q3 25 | $1.4B | $9.2M | ||
| Q2 25 | $1.3B | $151.3M | ||
| Q1 25 | $1.3B | $144.2M | ||
| Q4 24 | $1.3B | $255.0M | ||
| Q3 24 | $1.3B | $346.8M | ||
| Q2 24 | $1.2B | $432.4M | ||
| Q1 24 | $1.2B | $140.3M |
| Q4 25 | $12.5B | $1.5B | ||
| Q3 25 | $12.2B | $1.2B | ||
| Q2 25 | $12.2B | $1.3B | ||
| Q1 25 | $11.7B | $1.3B | ||
| Q4 24 | $11.5B | $1.5B | ||
| Q3 24 | $11.5B | $1.5B | ||
| Q2 24 | $11.3B | $1.6B | ||
| Q1 24 | $11.2B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $217.7M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $199.3M | $-100.8M |
| 自由现金流率自由现金流/营收 | 108.1% | -48.6% |
| 资本支出强度资本支出/营收 | 10.0% | 0.5% |
| 现金转化率经营现金流/净利润 | 3.90× | — |
| 过去12个月自由现金流最近4个季度 | $345.4M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $217.7M | $-99.8M | ||
| Q3 25 | $39.5M | $-91.4M | ||
| Q2 25 | $35.9M | $-108.3M | ||
| Q1 25 | $83.1M | $-166.5M | ||
| Q4 24 | $252.5M | $-79.3M | ||
| Q3 24 | $58.1M | $-67.0M | ||
| Q2 24 | $95.1M | $-77.0M | ||
| Q1 24 | $61.0M | $-190.7M |
| Q4 25 | $199.3M | $-100.8M | ||
| Q3 25 | $35.5M | $-92.7M | ||
| Q2 25 | $31.8M | $-110.7M | ||
| Q1 25 | $78.7M | $-167.8M | ||
| Q4 24 | $231.2M | $-79.5M | ||
| Q3 24 | $51.8M | $-68.6M | ||
| Q2 24 | $90.4M | $-79.0M | ||
| Q1 24 | $54.8M | $-193.9M |
| Q4 25 | 108.1% | -48.6% | ||
| Q3 25 | 19.1% | -58.0% | ||
| Q2 25 | 17.4% | -66.5% | ||
| Q1 25 | 44.1% | -120.5% | ||
| Q4 24 | 126.5% | -48.3% | ||
| Q3 24 | 29.6% | -49.2% | ||
| Q2 24 | 50.3% | -53.7% | ||
| Q1 24 | 31.4% | -178.2% |
| Q4 25 | 10.0% | 0.5% | ||
| Q3 25 | 2.1% | 0.8% | ||
| Q2 25 | 2.3% | 1.5% | ||
| Q1 25 | 2.4% | 1.0% | ||
| Q4 24 | 11.7% | 0.1% | ||
| Q3 24 | 3.6% | 1.2% | ||
| Q2 24 | 2.6% | 1.4% | ||
| Q1 24 | 3.5% | 3.0% |
| Q4 25 | 3.90× | — | ||
| Q3 25 | 0.76× | — | ||
| Q2 25 | 0.69× | — | ||
| Q1 25 | 1.82× | — | ||
| Q4 24 | 5.02× | — | ||
| Q3 24 | 1.24× | — | ||
| Q2 24 | 1.86× | — | ||
| Q1 24 | 1.23× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFG
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
